Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute heart failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    511 result(s) found for: Acute heart failure. Displaying page 26 of 26.
    «« First « Previous 18  19  20  21  22  23  24  25  26 
    EudraCT Number: 2016-000276-23 Sponsor Protocol Number: 201464 Start Date*: 2016-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
    Medical condition: Systemic amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001032-12 Sponsor Protocol Number: PANTHERA Start Date*: 2008-10-28
    Sponsor Name:Universitätsklinikum Schleswig-Holstein
    Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2020-002911-23 Sponsor Protocol Number: DS102A-08-CV2 Start Date*: 2020-10-12
    Sponsor Name:Afimmune
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study to Assess the Mechanism of Action and Safety of Orally Administered Epeleuton in Patients with Type 2 Diabetes and Diabet...
    Medical condition: Type 2 diabetes and diabetic complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000506-52 Sponsor Protocol Number: SE-866/44 Start Date*: 2005-02-22
    Sponsor Name:Sankyo Pharma GmbH
    Full Title: Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study
    Medical condition: NIDDM (non insulin dependent diabetes mellitus)
    Disease: Version SOC Term Classification Code Term Level
    10029402
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) EE (Completed) LV (Completed) IT (Completed) GB (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004887-74 Sponsor Protocol Number: AC-065D301 Start Date*: 2019-08-14
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
    Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002841-19 Sponsor Protocol Number: GEICAM/2006-11 Start Date*: 2007-08-23
    Sponsor Name:Grupo Español de Investigación en Cáncer de Mama (GEICAM)
    Full Title: "Estudio aleatorizado, multicéntrico para evaluar la eficacia y seguridad de bevacizumab en combinación con letrozol comparado con letrozol solo, en mujeres postmenopáusicas con cáncer de mama loca...
    Medical condition: Mujeres postmenopáusicas con cáncer de mama localmente recurrente o metastásico con indicación de hormonoterapia como tratamiento de primera linea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006275 Breast metastases LLT
    9.1 10006212 Breast carcinoma recurrent LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003577-27 Sponsor Protocol Number: A6631007 Start Date*: 2006-12-01
    Sponsor Name:Pfizer Luxembourg SARL Branch Office Estonia
    Full Title: A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE...
    Medical condition: Treatment of rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002874-19 Sponsor Protocol Number: 63935937MDS3001 Start Date*: 2015-11-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Sti...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000199-20 Sponsor Protocol Number: ML43171 Start Date*: 2022-07-27
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-...
    Medical condition: Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000768-27 Sponsor Protocol Number: BAY59-7939/16573 Start Date*: 2015-01-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients w...
    Medical condition: Embolic stroke of undetermined source (ESUS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) PT (Prematurely Ended) CZ (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) FI (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 18  19  20  21  22  23  24  25  26 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 10:12:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA